192 related articles for article (PubMed ID: 33376323)
1. Aptamer-Functionalized Dendrimer Delivery of Plasmid-Encoding lncRNA
Tai Z; Ma J; Ding J; Pan H; Chai R; Zhu C; Cui Z; Chen Z; Zhu Q
Int J Nanomedicine; 2020; 15():10305-10320. PubMed ID: 33376323
[TBL] [Abstract][Full Text] [Related]
2. Plasmid pORF-hTRAIL targeting to glioma using transferrin-modified polyamidoamine dendrimer.
Gao S; Li J; Jiang C; Hong B; Hao B
Drug Des Devel Ther; 2016; 10():1-11. PubMed ID: 26719669
[TBL] [Abstract][Full Text] [Related]
3. Co-delivery of doxorubicin and TRAIL plasmid by modified PAMAM dendrimer in colon cancer cells,
Pishavar E; Ramezani M; Hashemi M
Drug Dev Ind Pharm; 2019 Dec; 45(12):1931-1939. PubMed ID: 31609130
[TBL] [Abstract][Full Text] [Related]
4. Dual targeting effect of Angiopep-2-modified, DNA-loaded nanoparticles for glioma.
Huang S; Li J; Han L; Liu S; Ma H; Huang R; Jiang C
Biomaterials; 2011 Oct; 32(28):6832-8. PubMed ID: 21700333
[TBL] [Abstract][Full Text] [Related]
5. The role of caveolin-1 and syndecan-4 in the internalization of PEGylated PAMAM dendrimer polyplexes into myoblast and hepatic cells.
Shen W; van Dongen MA; Han Y; Yu M; Li Y; Liu G; Banaszak Holl MM; Qi R
Eur J Pharm Biopharm; 2014 Nov; 88(3):658-63. PubMed ID: 25083608
[TBL] [Abstract][Full Text] [Related]
6. lncRNA HOXD-AS1 Regulates Proliferation and Chemo-Resistance of Castration-Resistant Prostate Cancer via Recruiting WDR5.
Gu P; Chen X; Xie R; Han J; Xie W; Wang B; Dong W; Chen C; Yang M; Jiang J; Chen Z; Huang J; Lin T
Mol Ther; 2017 Aug; 25(8):1959-1973. PubMed ID: 28487115
[TBL] [Abstract][Full Text] [Related]
7. Aptamer-mediated gene therapy enhanced antitumor activity against human hepatocellular carcinoma in vitro and in vivo.
Xiao S; Liu Z; Deng R; Li C; Fu S; Chen G; Zhang X; Ke F; Ke S; Yu X; Wang S; Zhong Z
J Control Release; 2017 Jul; 258():130-145. PubMed ID: 28522194
[TBL] [Abstract][Full Text] [Related]
8. Aptamer-Conjugated Multifunctional Polymeric Nanoparticles as Cancer-Targeted, MRI-Ultrasensitive Drug Delivery Systems for Treatment of Castration-Resistant Prostate Cancer.
Fang Y; Lin S; Yang F; Situ J; Lin S; Luo Y
Biomed Res Int; 2020; 2020():9186583. PubMed ID: 32420382
[TBL] [Abstract][Full Text] [Related]
9. A novel RGDyC/PEG co-modified PAMAM dendrimer-loaded arsenic trioxide of glioma targeting delivery system.
Lu Y; Han S; Zheng H; Ma R; Ping Y; Zou J; Tang H; Zhang Y; Xu X; Li F
Int J Nanomedicine; 2018; 13():5937-5952. PubMed ID: 30323584
[TBL] [Abstract][Full Text] [Related]
10. Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors.
Han L; Huang R; Liu S; Huang S; Jiang C
Mol Pharm; 2010 Dec; 7(6):2156-65. PubMed ID: 20857964
[TBL] [Abstract][Full Text] [Related]
11. α-Tocopherol Succinate-Anchored PEGylated Poly(amidoamine) Dendrimer for the Delivery of Paclitaxel: Assessment of in Vitro and in Vivo Therapeutic Efficacy.
Bhatt H; Kiran Rompicharla SV; Ghosh B; Biswas S
Mol Pharm; 2019 Apr; 16(4):1541-1554. PubMed ID: 30817166
[TBL] [Abstract][Full Text] [Related]
12. Codelivery of GRP78 siRNA and docetaxel via RGD-PEG-DSPE/DOPA/CaP nanoparticles for the treatment of castration-resistant prostate cancer.
Zhang X; He Z; Xiang L; Li L; Zhang H; Lin F; Cao H
Drug Des Devel Ther; 2019; 13():1357-1372. PubMed ID: 31118572
[No Abstract] [Full Text] [Related]
13. Target-specific delivery of doxorubicin to retinoblastoma using epithelial cell adhesion molecule aptamer.
Subramanian N; Raghunathan V; Kanwar JR; Kanwar RK; Elchuri SV; Khetan V; Krishnakumar S
Mol Vis; 2012; 18():2783-95. PubMed ID: 23213278
[TBL] [Abstract][Full Text] [Related]
14. A Novel DNA Aptamer Probe Recognizing Castration Resistant Prostate Cancer in vitro and in vivo Based on Cell-SELEX.
Zhong J; Liu D; Yang Q; Ding J; Chen X
Drug Des Devel Ther; 2024; 18():859-870. PubMed ID: 38524880
[TBL] [Abstract][Full Text] [Related]
15. Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy.
Wu X; Ding B; Gao J; Wang H; Fan W; Wang X; Zhang W; Wang X; Ye L; Zhang M; Ding X; Liu J; Zhu Q; Gao S
Int J Nanomedicine; 2011; 6():1747-56. PubMed ID: 21980237
[TBL] [Abstract][Full Text] [Related]
16. Transferrin Conjugated pH- and Redox-Responsive Poly(Amidoamine) Dendrimer Conjugate as an Efficient Drug Delivery Carrier for Cancer Therapy.
Hu Q; Wang Y; Xu L; Chen D; Cheng L
Int J Nanomedicine; 2020; 15():2751-2764. PubMed ID: 32368053
[TBL] [Abstract][Full Text] [Related]
17. Poly (amidoamine) (PAMAM) dendrimer mediated delivery of drug and pDNA/siRNA for cancer therapy.
Li J; Liang H; Liu J; Wang Z
Int J Pharm; 2018 Jul; 546(1-2):215-225. PubMed ID: 29787895
[TBL] [Abstract][Full Text] [Related]
18. An oligopeptide/aptamer-conjugated dendrimer-based nanocarrier for dual-targeting delivery to bone.
Ren M; Li Y; Zhang H; Li L; He P; Ji P; Yang S
J Mater Chem B; 2021 Mar; 9(12):2831-2844. PubMed ID: 33704322
[TBL] [Abstract][Full Text] [Related]
19. A novel dendritic nanocarrier of polyamidoamine-polyethylene glycol-cyclic RGD for "smart" small interfering RNA delivery and in vitro antitumor effects by human ether-à-go-go-related gene silencing in anaplastic thyroid carcinoma cells.
Li G; Hu Z; Yin H; Zhang Y; Huang X; Wang S; Li W
Int J Nanomedicine; 2013; 8():1293-306. PubMed ID: 23569377
[TBL] [Abstract][Full Text] [Related]
20. Thioaptamer-conjugated CD44-targeted delivery system for the treatment of breast cancer in vitro and in vivo.
Fan W; Wang X; Ding B; Cai H; Wang X; Fan Y; Li Y; Liu S; Nie S; Lu Q
J Drug Target; 2016; 24(4):359-71. PubMed ID: 26299192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
